Our study suggests that treatment options that abrogate the TGFB2 mRNA expression, such as OT-101 [57,58], combined with the delivery of interferon-gamma to the tumor microenvironment can improve the survival outcomes of pbDMG patients. This evidence concerns the gene IFNG and neoplasm.